P
Peter Kern
Publications - 3
Citations - 611
Peter Kern is an academic researcher. The author has contributed to research in topics: Neuromyelitis optica & Myelitis. The author has an hindex of 3, co-authored 3 publications receiving 523 citations.
Papers
More filters
Journal ArticleDOI
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
Sven Jarius,Klemens Ruprecht,Brigitte Wildemann,Tania Kuempfel,Marius Ringelstein,Christian Geis,Ingo Kleiter,Ingo Kleiter,Christoph Kleinschnitz,Achim Berthele,Johannes Brettschneider,Kerstin Hellwig,Bernhard Hemmer,Ralf A. Linker,Ralf A. Linker,Florian Lauda,Christoph Mayer,Hayrettin Tumani,Arthur Melms,Corinna Trebst,Martin Stangel,Martin Marziniak,Frank Hoffmann,Sven Schippling,Jürgen H. Faiss,Oliver Neuhaus,Barbara Ettrich,Christian Zentner,Kersten Guthke,Ulrich Hofstadt-van Oy,Reinhard Reuss,Hannah L. Pellkofer,Ulf Ziemann,Peter Kern,Klaus Peter Wandinger,Florian Then Bergh,Tobias Boettcher,Stefan Langel,Martin Liebetrau,Paulus S. Rommer,Sabine Niehaus,Christoph Münch,Alexander Winkelmann,Uwe K Zettl U,Imke Metz,Christian Veauthier,Jörn P Sieb,C. Wilke,Hans Hartung,Orhan Aktas,Friedemann Paul +50 more
TL;DR: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
Journal ArticleDOI
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
Markus Krumbholz,Ulrich Hofstadt-van Oy,Klemens Angstwurm,Ingo Kleiter,Sven Jarius,Friedemann Paul,Orhan Aktas,Grete Buchholz,Peter Kern,Andreas Straube,Tania Kümpfel +10 more
TL;DR: It is concluded that a first manifestation of NMOSD should be considered even in patients beyond the age of 75 years with a compatible syndrome, especially longitudinally extensive myelitis, and special attention is warranted in the elderly to recognize adverse effects of immunosuppressive therapies as early as possible.
Journal ArticleDOI
7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
Tim Sinnecker,Jalal Othman,Marc Kühl,Ralf Mekle,Inga Selbig,Thoralf Niendorf,Annett Kunkel,Peter Wienecke,Peter Kern,Friedemann Paul,Juergen Faiss,Jens Wuerfel +11 more
TL;DR: The ability of ultra-high-field MRI to distinguish early progressive multifocal leukoencephalopathy (PML) from multiple sclerosis (MS) lesions in a rare case of simultaneous presentation of natalizumab–associated PML and ongoing MS activity is assessed.